Price$56.66-15.79 (-21.79%)
2026-03-052026-06-08
News · 26 weeks62-70%
2025-12-142026-06-07
Mix3390d
- SEC Filings12(36%)
- Other9(27%)
- Offering5(15%)
- Insider3(9%)
- Analyst2(6%)
- Earnings2(6%)
Latest news
25 items- SECNektar Therapeutics filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
- PRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 11,900 shares of its common stock to five newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar
- PRNektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New YorkSAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York. 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 – webcast to be available at 1:20 p.m. Eastern Time – webcast link hereThe fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A
- INSIDERSEC Form 3 filed by new insider Rubinstein Linda M3 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- INSIDERChief R&D Officer Zalevsky Jonathan sold $13,036 worth of shares (199 units at $65.51), decreasing direct ownership by 0.94% to 20,975 units (SEC Form 4) (withholding tax)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- INSIDERPresident & CEO Robin Howard W sold $29,086 worth of shares (444 units at $65.51), decreasing direct ownership by 0.59% to 75,045 units (SEC Form 4) (tax withholding)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Nektar TherapeuticsSCHEDULE 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
- SECSEC Form 424B5 filed by Nektar Therapeutics424B5 - NEKTAR THERAPEUTICS (0000906709) (Filer)
- SECSEC Form 8-K filed by Nektar Therapeutics8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
- SECNektar Therapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
- PRNektar Therapeutics Reports First Quarter 2026 Financial ResultsSAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the first quarter ended March 31, 2026. Cash and investments in marketable securities on March 31, 2026, were $731.6 million as compared to $245.8 million on December 31, 2025. Nektar's cash and marketable securities at March 31, 2026, exclude net proceeds of approximately $351 million from the secondary offering completed by the Company on April 23, 2026."2026 is shaping up to be a defining year for Nektar and for our lead biologic candidate rezpegaldesleukin," said
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Nektar TherapeuticsSCHEDULE 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
- PRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, May 1, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 28,450 shares of its common stock and 2,950 restricted stock units (RSUs) to six newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an emp
- PRNektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial MarketsSAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 7, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The we
- SECSEC Form DEFA14A filed by Nektar TherapeuticsDEFA14A - NEKTAR THERAPEUTICS (0000906709) (Filer)
- SECSEC Form DEF 14A filed by Nektar TherapeuticsDEF 14A - NEKTAR THERAPEUTICS (0000906709) (Filer)
- PRNektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesSAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the closing of its underwritten public offering of $373.8 million of shares of its common stock. Nektar sold 4,062,500 shares of common stock in the offering, which includes 529,891 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The shares of common stock were sold at a public offering price of $92.00 per share. The gross proceeds to Nektar from the offering were approximately $373.8 million, before deducting underwritin
- SECSEC Form 8-K filed by Nektar Therapeutics8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
- SECSEC Form 424B5 filed by Nektar Therapeutics424B5 - NEKTAR THERAPEUTICS (0000906709) (Filer)
- PRNektar Therapeutics Announces Pricing of Upsized $325 Million Public OfferingSAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $325 million of shares of its common stock. Nektar is selling 3,532,609 shares of common stock at a public offering price of $92.00 per share. The gross proceeds to Nektar from the offering are expected to be approximately $325 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Nektar has granted the underwriters a 30-day option to purchase up to an additional
- SECSEC Form 424B5 filed by Nektar Therapeutics424B5 - NEKTAR THERAPEUTICS (0000906709) (Filer)
- SECNektar Therapeutics filed SEC Form 8-K: Regulation FD Disclosure8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
- PRNektar Therapeutics Announces Proposed Public OfferingSAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten public offering of $250,000,000 of its shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Nektar. In addition, Nektar intends to grant the underwriters a 30-day option to purchase up to an additional $37,500,000 of shares of its common stock at the p
- SECNektar Therapeutics filed SEC Form 8-K: Regulation FD Disclosure8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
- PR52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin29% and 31% of patients in the 18 µg/kg and 24 µg/kg extension arms, respectively, achieved new SALT Score ≤20 from week 36 to week 52 with continued twice-monthly treatmentIncreasing proportions of patients achieved clinically meaningful hair growth thresholds across numerous SALT measurements with 94% of patients completing treatment extensionFavorable safety profile with twice-monthly dosing maintained throughout 52 weeks, consistent with previously reported resultsResults support advancement of rezpegaldesleukin into late-stage development in alopecia areataSAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on d
NKTR FAQ
6 questionsWhat does Nektar Therapeutics do?
Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to...Where does NKTR stock trade?
Nektar Therapeutics (NKTR) is listed on NASDAQ.What sector and industry is NKTR in?
Nektar Therapeutics operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about NKTR?
Nektar Therapeutics has had 8 recent analyst actions on file. The most recent action was from Wedbush: Neutral on 2026-03-24. Recent price targets range from $200.00 to $600.00.What companies are similar to NKTR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NKTR side-by-side with any of them on Quantisnow.How can I track NKTR on Quantisnow?
Quantisnow aggregates Nektar Therapeutics's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NKTR to receive live email and push alerts on every new disclosure.